PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Jean-Damien Charrier	07/16/2013
Pierre-Henri Storck	07/16/2013
John Studley	07/31/2013
Francoise Yvonne Theodora Marie Pierard	07/17/2013

RECEIVING PARTY DATA

Name:	Vertex Pharmaceuticals (Europe) Limited
Street Address:	86-88 Jubilee Avenue
Internal Address:	Milton Park
City:	Abingdon, Oxfordshire
State/Country:	UNITED KINGDOM
Postal Code:	OX14 4RW

PROPERTY NUMBERS Total: 2

Property Type	Number	
Application Number:	13631727	
PCT Number:	US2012058119	

CORRESPONDENCE DATA

Fax Number: 6173416483

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 617-341-6100

Email: Carolyn_Anderson@vrtx.com

Correspondent Name: Vertex Pharmaceuticals Incorporated

Address Line 1: 130 Waverly Street

Address Line 4: Cambridge, MASSACHUSETTS 02139

ATTORNEY DOCKET NUMBER:	VPI/11-130 US AND WO
NAME OF SUBMITTER:	Carolyn Anderson
	PAIENI

502453859 REEL: 030985 FRAME: 0787

1363/1/27

Signature:	/Carolyn Anderson/
Date:	08/12/2013
Total Attachments: 7 source=11-130USWO-inventors-to-UK#pag source=11-130USWO-inventors-to-UK#pag source=11-130USWO-inventors-to-UK#pag source=11-130USWO-inventors-to-UK#pag source=11-130USWO-inventors-to-UK#pag source=11-130USWO-inventors-to-UK#pag	e2.tif e3.tif e4.tif e5.tif e6.tif

PATENT REEL: 030985 FRAME: 0788

ASSIGNMENT

We,

- (1) Jean-Damien Charrier, of Grove, Wantage, Oxfordshire, United Kingdom;
- (2) Pierre-Henri Storck, of Abingdon, Oxfordshire, United Kingdom;
- (3) John Studley, of Witney, Oxfordshire, United Kingdom; and
- (4) Françoise Yvonne Theodora Marie Pierard, of Abingdon, Oxfordshire, United Kingdom;

for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to, by virtue of our agreement with Vertex Pharmaceuticals (Europe) Limited, and do hereby assign, sell and transfer to, Vertex Pharmaceuticals (Europe) Limited, a company registered in England and Wales under registered number 02907620 and having an office and a place of business at 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW U.K., its successors and assigns, all hereinafter referred to as the ASSIGNEE:

- (1) the entire right, title and interest in all countries throughout the world in and to any and all of my/our inventions, and discoveries disclosed in:
- (a) the application for United States Letters Patent entitled: COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE, and filed in the United States Patent and Trademark Office on September 28, 2012, under Application Number 13/631,727, including any renewals, revivals, reissues, reexaminations, extensions, continuations, and divisions thereof, and any substitute applications therefor, and/or
- (b) the International Patent Application entitled: COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE, filed under the Patent Cooperation Treaty in the United States Receiving Office on September 28, 2012, under Application No. PCT/US2012/058119, and designating all countries, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof, and any substitute applications therefor;
- (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in my/our names at the election of the ASSIGNEE or its designee, on the aforesaid inventions, discoveries and applications in any country throughout the world;
- (3) the entire right, title and interest in and to any Letters Patent which may issue thereon in any country throughout the world, and in and to any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof; and

Page 1 of 7

(4) the entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications including, but not limited to, the following priority application(s):

61/541,869	US	September 30, 2011
Application No.	Country	Filing Date
61/554,180	US	November 11, 2011
Application No.	Country	Filing Date
61/620,704	US	April 5, 2012
Application No.	Country	Filing Date

and all rights of priority in any country of the world deriving from the above-identified International Patent Application.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by me/us had this assignment, sale and transfer not been made.

We agree, at any time, upon the request of the ASSIGNEE to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

We further agree at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

Vertex Pharmaceuticals (Europe) Limited Attorney Docket No.; VPI/11-130 US and WO

(1) Jean-Damien Charrier

Date: 16th Jlg 2003

IN WITNESS WHEREOF, I have hereunto set hand and seal

:		
e e e e e e e e e e e e e e e e e e e	the same of the sa	
(2) Pierre	e-Henri Storck	
Date:	16/07/2013	
	WC 39	

IN WITNESS WHEREOF, I have hereunto set hand and seal

Signature of witness: (1) Roy Lawar	<u></u>
Printed Name of Witness: Rory STEW	anet .
this 16th day of July 2013 Date of signing	
Signature of witness: (2)	site motions
Printed Name of Witness: Aneta	Stansba
this day of Deth of signing	

SUC
(3) John Studley Date:
IN WITNESS WHEREOF, I have hereunto set hand and seal
Signature of witness: (1)
Printed Name of Witness: H. MELLOR
this 31st day of July 2013. Date of signing
Signature of witness: (2) Flory Javan T
Printed Name of Witness: Roky Sewaret
this 31st day of July 2013. Date of signing

	(4) Françoise Yvonne Theodora Marie Pierard
	Date: 17 July 2013
IN WITNESS WHEREOF, I have hereunto	set hand and seal
Signature of witness: (1)	more
Printed Name of Witness: M. Mulai M	ORE
this 17th day of July 2013 Date of signing	<u>) </u>
Signature of witness: (2)	et
Printed Name of Witness: Rory Stev	VART
this 17th day of July 2013 Date of signing	3

Vertex Pharmaceuticals (Europe) Limited Attorney Docket No.: VPI/11-130 US and WO

ACKNOWLEDGMENT OF ASSIGNEE

By: ______

Stephen L. Nesbitt

Vice President and Chief IP Counsel

VERTEX PHARMACEUTICALS INCORPORATED

Date: 8/7/3

Commonwealth of Massachusetts

County of Middlesex

Notary Public

My Commission Expires: 574

Page 7 of 7